Cargando…

Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial

Human parvovirus B19 (B19V) is the predominant virus currently detected in endomyocardial biopsies (EMBs). Recent findings indicate that, specifically, transcriptionally active B19V with detectable viral RNA is of prognostic relevance in inflammatory viral cardiomyopathy. We aimed to evaluate B19V r...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultheiss, Heinz-Peter, Bock, Claus-Thomas, Aleshcheva, Ganna, Baumeier, Christian, Poller, Wolfgang, Escher, Felicitas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875228/
https://www.ncbi.nlm.nih.gov/pubmed/35216037
http://dx.doi.org/10.3390/v14020444
_version_ 1784657867780915200
author Schultheiss, Heinz-Peter
Bock, Claus-Thomas
Aleshcheva, Ganna
Baumeier, Christian
Poller, Wolfgang
Escher, Felicitas
author_facet Schultheiss, Heinz-Peter
Bock, Claus-Thomas
Aleshcheva, Ganna
Baumeier, Christian
Poller, Wolfgang
Escher, Felicitas
author_sort Schultheiss, Heinz-Peter
collection PubMed
description Human parvovirus B19 (B19V) is the predominant virus currently detected in endomyocardial biopsies (EMBs). Recent findings indicate that, specifically, transcriptionally active B19V with detectable viral RNA is of prognostic relevance in inflammatory viral cardiomyopathy. We aimed to evaluate B19V replicative status (viral RNA) and beneficial effects in a sub-collective of the prospective randomized placebo-controlled phase II multi-center BICC-Trial (Betaferon In Chronic Viral Cardiomyopathy) after interferon beta-1b (IFN-β) treatment. EMBs of n = 64 patients with B19V mono-infected tissue were retrospectively analyzed. Viral RNA could be detected in n = 18/64 (28.1%) of B19V DNA positive samples (mean age 51.7 years, 12 male), of whom n = 13 had been treated with IFN-ß. Five patients had received placebo. PCR analysis confirmed in follow-up that EMBs significantly reduced viral RNA loads in n = 11/13 (84.6%) of IFN-ß treated patients (p = 0.001), independently from the IFN-ß dose, in contrast to the placebo group, where viral RNA load was not affected or even increased. Consequently, a significant improvement of left ventricular ejection fraction (LVEF) after treatment with IFN-ß was observed (LVEF mean baseline 51.6 ± 14.1% vs. follow-up 61.0 ± 17.5%, p = 0.03). In contrast, in the placebo group, worsening of LVEF was evaluated in n = 4/5 (80.0%) of patients. We could show for the first-time the beneficial effects from treatment with IFN-ß, suppressing B19V viral RNA and improving the hemodynamic course. Our results need further verification in a larger prospective randomized controlled trial.
format Online
Article
Text
id pubmed-8875228
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88752282022-02-26 Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial Schultheiss, Heinz-Peter Bock, Claus-Thomas Aleshcheva, Ganna Baumeier, Christian Poller, Wolfgang Escher, Felicitas Viruses Communication Human parvovirus B19 (B19V) is the predominant virus currently detected in endomyocardial biopsies (EMBs). Recent findings indicate that, specifically, transcriptionally active B19V with detectable viral RNA is of prognostic relevance in inflammatory viral cardiomyopathy. We aimed to evaluate B19V replicative status (viral RNA) and beneficial effects in a sub-collective of the prospective randomized placebo-controlled phase II multi-center BICC-Trial (Betaferon In Chronic Viral Cardiomyopathy) after interferon beta-1b (IFN-β) treatment. EMBs of n = 64 patients with B19V mono-infected tissue were retrospectively analyzed. Viral RNA could be detected in n = 18/64 (28.1%) of B19V DNA positive samples (mean age 51.7 years, 12 male), of whom n = 13 had been treated with IFN-ß. Five patients had received placebo. PCR analysis confirmed in follow-up that EMBs significantly reduced viral RNA loads in n = 11/13 (84.6%) of IFN-ß treated patients (p = 0.001), independently from the IFN-ß dose, in contrast to the placebo group, where viral RNA load was not affected or even increased. Consequently, a significant improvement of left ventricular ejection fraction (LVEF) after treatment with IFN-ß was observed (LVEF mean baseline 51.6 ± 14.1% vs. follow-up 61.0 ± 17.5%, p = 0.03). In contrast, in the placebo group, worsening of LVEF was evaluated in n = 4/5 (80.0%) of patients. We could show for the first-time the beneficial effects from treatment with IFN-ß, suppressing B19V viral RNA and improving the hemodynamic course. Our results need further verification in a larger prospective randomized controlled trial. MDPI 2022-02-21 /pmc/articles/PMC8875228/ /pubmed/35216037 http://dx.doi.org/10.3390/v14020444 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Schultheiss, Heinz-Peter
Bock, Claus-Thomas
Aleshcheva, Ganna
Baumeier, Christian
Poller, Wolfgang
Escher, Felicitas
Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
title Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
title_full Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
title_fullStr Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
title_full_unstemmed Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
title_short Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
title_sort interferon-β suppresses transcriptionally active parvovirus b19 infection in viral cardiomyopathy: a subgroup analysis of the bicc-trial
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875228/
https://www.ncbi.nlm.nih.gov/pubmed/35216037
http://dx.doi.org/10.3390/v14020444
work_keys_str_mv AT schultheissheinzpeter interferonbsuppressestranscriptionallyactiveparvovirusb19infectioninviralcardiomyopathyasubgroupanalysisofthebicctrial
AT bockclausthomas interferonbsuppressestranscriptionallyactiveparvovirusb19infectioninviralcardiomyopathyasubgroupanalysisofthebicctrial
AT aleshchevaganna interferonbsuppressestranscriptionallyactiveparvovirusb19infectioninviralcardiomyopathyasubgroupanalysisofthebicctrial
AT baumeierchristian interferonbsuppressestranscriptionallyactiveparvovirusb19infectioninviralcardiomyopathyasubgroupanalysisofthebicctrial
AT pollerwolfgang interferonbsuppressestranscriptionallyactiveparvovirusb19infectioninviralcardiomyopathyasubgroupanalysisofthebicctrial
AT escherfelicitas interferonbsuppressestranscriptionallyactiveparvovirusb19infectioninviralcardiomyopathyasubgroupanalysisofthebicctrial